Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Standards of Care II01:19

Standards of Care II

Nurses bear specific legal responsibilities under several federal statutes, including:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026
Same author

Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.

Nature communications·2026
Same author

SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST).

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.

Future oncology (London, England)·2025
Same author

Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration.

Journal of immunotherapy and precision oncology·2025
Same author

Succinate Dehydrogenase B (SDHB) Overexpression with Enzymatic Dysfunction Defines a Distinct Subtype of Undifferentiated Pleomorphic Sarcoma.

Cancer research communications·2025

Related Experiment Video

Updated: May 19, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines.

Margaret von Mehren1, Robert S Benjamin, Marilyn M Bui

  • 1Fox Chase Cancer Center, USA.

Journal of the National Comprehensive Cancer Network : JNCCN
|August 11, 2012
PubMed
Summary
This summary is machine-generated.

The NCCN Guidelines for Soft Tissue Sarcoma now recommend postoperative imatinib for high-risk gastrointestinal stromal tumors (GISTs) and offer observation or sorafenib for desmoid tumors.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Related Experiment Videos

Last Updated: May 19, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Area of Science:

  • Oncology
  • Clinical Practice Guidelines
  • Soft Tissue Sarcoma Management

Background:

  • The National Comprehensive Cancer Network (NCCN) Guidelines provide crucial updates for managing soft tissue sarcomas.
  • Significant revisions focus on gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis).

Purpose of the Study:

  • To summarize key changes in the 2011 and 2012 NCCN Guidelines for Soft Tissue Sarcoma.
  • To highlight updated recommendations for GIST and desmoid tumor patient management.

Main Methods:

  • Review and synthesis of the 2011 and 2012 NCCN Guidelines for Soft Tissue Sarcoma.
  • Identification of specific changes related to GIST and desmoid tumor treatment protocols.

Main Results:

  • Postoperative imatinib is a Category 1 recommendation for primary GIST patients with intermediate or high recurrence risk after complete resection without neoadjuvant imatinib.
  • Preoperative imatinib is reaffirmed for resectable GISTs with clear margins but high surgical morbidity.
  • Observation is now an option for small, asymptomatic, resectable desmoid tumors without morbidity.
  • Sorafenib is introduced as a systemic therapy option for desmoid tumors.

Conclusions:

  • Updated NCCN Guidelines offer refined management strategies for GIST and desmoid tumors.
  • New recommendations provide more options, including imatinib and sorafenib, and non-operative approaches, improving patient care pathways.